Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Edgewise Therapeutics, Inc. - Common Stock (NQ:EWTX)

41.96 -0.02 (-0.05%)
Streaming Delayed Price Updated: 9:59 AM EDT, Sep 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 80,111
Open 42.32
Bid (Size) 41.82 (200)
Ask (Size) 42.10 (100)
Prev. Close 41.98
Today's Range 41.50 - 42.99
52wk Range 13.69 - 48.40
Shares Outstanding 105,341,296
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Biotech Fund Sells $44.5 Million Erasca Stake After Massive 700% Rally ↗
This clinical-stage biotech develops targeted therapies for RAS/MAPK pathway cancers, advancing a pipeline of novel oncology candidates. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter ↗
Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through proprietary TYK2 inhibitors. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
+76.7%
+76.7%
1 Month
+9.3%
+9.3%
3 Month
+15.9%
+15.9%
6 Month
+45.3%
+45.3%
1 Year
+182.4%
+182.4%

More News

Read More
News headline image
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally ↗
Via The Motley Fool
Edgewise Therapeutics (NASDAQ:EWTX) Beats Q1 Estimates as Long-Term Data Strengthens Case for Sevasemten ↗
Via Chartmill
News headline image
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What to Know About This Fund’s $50 Million Exit From Ascendis Pharma ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO ↗
Via The Motley Fool
Topics Initial Public Offering
News headline image
Why This Hedge Fund Added $29 Million to a Cancer Stock Already Up 700% ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why Edgewise Therapeutics Stock Topped the Market on Tuesday ↗
Via The Motley Fool
News headline image
This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on Shares ↗
Via The Motley Fool
News headline image
This Investor Built a $56 Million Position in RAPT Last Quarter. It Was Just Acquired for $58 Per Share ↗
Via The Motley Fool
News headline image
ORBIMED Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Inside a $58 Million Bet on Kodiak Amid $184 Million Offering and Phase 3 Readouts Ahead ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Just Disclosed a New $55 Million Bet on Centessa Amid 53% Stock Rally and CEO Transition ↗
Via The Motley Fool
News headline image
CG Oncology Soars 102% in a Year, but One Investor Just Disclosed a $58.5 Million Sale ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
BrightSpring Stock Up 86% as Braidwell Takes $45 Million Stake in Healthcare Services Provider ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites ↗
Via Stocktwits
News headline image
Why Edgewise Therapeutics Stock Crushed the Market on Monday ↗
Via The Motley Fool
News headline image
This Biotech Fund Exited an $8 Million Edgewise Stake as the Stock Slid Double Digits ↗
Via The Motley Fool
News headline image
Why Edgewise Therapeutics Stock Rocked the Market Today ↗
Via The Motley Fool
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
News headline image
Edgewise Therapeutics Stock Jumps After Trial Update For Genetic Heart Disease — Wall Street Eyes A Potential Standout ↗
Via Stocktwits
News headline image
Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results
Via MarketMinute
News headline image
This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance

Frequently Asked Questions

Is Edgewise Therapeutics, Inc. - Common Stock publicly traded?
Yes, Edgewise Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Edgewise Therapeutics, Inc. - Common Stock trade on?
Edgewise Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Edgewise Therapeutics, Inc. - Common Stock?
The ticker symbol for Edgewise Therapeutics, Inc. - Common Stock is EWTX on the Nasdaq Stock Market
What is the current price of Edgewise Therapeutics, Inc. - Common Stock?
The current price of Edgewise Therapeutics, Inc. - Common Stock is 41.96
When was Edgewise Therapeutics, Inc. - Common Stock last traded?
The last trade of Edgewise Therapeutics, Inc. - Common Stock was at 09/03/26 09:59 AM ET
What is the market capitalization of Edgewise Therapeutics, Inc. - Common Stock?
The market capitalization of Edgewise Therapeutics, Inc. - Common Stock is 4.42B
How many shares of Edgewise Therapeutics, Inc. - Common Stock are outstanding?
Edgewise Therapeutics, Inc. - Common Stock has 4B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.